These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 25534238)

  • 1. Incorporation of biomarkers in phase II studies of recurrent glioblastoma.
    Jue TR; Hovey E; Davis S; Carleton O; McDonald KL
    Tumour Biol; 2015 Jan; 36(1):153-62. PubMed ID: 25534238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials.
    Ellingson BM; Harris RJ; Woodworth DC; Leu K; Zaw O; Mason WP; Sahebjam S; Abrey LE; Aftab DT; Schwab GM; Hessel C; Lai A; Nghiemphu PL; Pope WB; Wen PY; Cloughesy TF
    Neuro Oncol; 2017 Jan; 19(1):89-98. PubMed ID: 27580889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastoma.
    Qazi MA; Vora P; Venugopal C; Sidhu SS; Moffat J; Swanton C; Singh SK
    Ann Oncol; 2017 Jul; 28(7):1448-1456. PubMed ID: 28407030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patupilone (epothilone B) for recurrent glioblastoma: clinical outcome and translational analysis of a single-institution phase I/II trial.
    Oehler C; Frei K; Rushing EJ; McSheehy PM; Weber D; Allegrini PR; Weniger D; Lütolf UM; Knuth A; Yonekawa Y; Barath K; Broggini-Tenzer A; Pruschy M; Hofer S
    Oncology; 2012; 83(1):1-9. PubMed ID: 22688083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eight-year survival of a recurrent glioblastoma patient treated with molecularly tailored therapy: a case report.
    D'Alessandris QG; Montano N; Martini M; Cenci T; Lauretti L; Stumpo V; Pignotti F; Olivi A; Fernandez E; Larocca LM; Pallini R
    Acta Neurochir (Wien); 2018 Dec; 160(12):2387-2391. PubMed ID: 30306271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
    Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
    Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
    Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
    Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological basis and clinical study of glycogen synthase kinase- 3β-targeted therapy by drug repositioning for glioblastoma.
    Furuta T; Sabit H; Dong Y; Miyashita K; Kinoshita M; Uchiyama N; Hayashi Y; Hayashi Y; Minamoto T; Nakada M
    Oncotarget; 2017 Apr; 8(14):22811-22824. PubMed ID: 28423558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of EGFR in Paired New and Recurrent Glioblastomas.
    Cioca A; Olteanu EG; Gisca MD; Morosanu CO; Marin I; Florian IS
    Asian Pac J Cancer Prev; 2016; 17(9):4205-4208. PubMed ID: 27797218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study.
    Butowski N; Colman H; De Groot JF; Omuro AM; Nayak L; Wen PY; Cloughesy TF; Marimuthu A; Haidar S; Perry A; Huse J; Phillips J; West BL; Nolop KB; Hsu HH; Ligon KL; Molinaro AM; Prados M
    Neuro Oncol; 2016 Apr; 18(4):557-64. PubMed ID: 26449250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolving strategies: future treatment of glioblastoma.
    Chamberlain M
    Expert Rev Neurother; 2011 Apr; 11(4):519-32. PubMed ID: 21469925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival kinase genes present prognostic significance in glioblastoma.
    Varghese RT; Liang Y; Guan T; Franck CT; Kelly DF; Sheng Z
    Oncotarget; 2016 Apr; 7(15):20140-51. PubMed ID: 26956052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma.
    Taylor JW; Parikh M; Phillips JJ; James CD; Molinaro AM; Butowski NA; Clarke JL; Oberheim-Bush NA; Chang SM; Berger MS; Prados M
    J Neurooncol; 2018 Nov; 140(2):477-483. PubMed ID: 30151703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression pattern and prognostic significance of myosin light chain 9 (MYL9): a novel biomarker in glioblastoma.
    Kruthika BS; Sugur H; Nandaki K; Arimappamagan A; Paturu K; Santosh V
    J Clin Pathol; 2019 Oct; 72(10):677-681. PubMed ID: 31270134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The challenges associated with molecular targeted therapies for glioblastoma.
    Jue TR; McDonald KL
    J Neurooncol; 2016 May; 127(3):427-34. PubMed ID: 26900075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New trends in the medical management of glioblastoma multiforme: the role of temozolomide chemotherapy.
    Dehdashti AR; Hegi ME; Regli L; Pica A; Stupp R
    Neurosurg Focus; 2006 Apr; 20(4):E6. PubMed ID: 16709037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Whole genome and biomarker analysis of patients with recurrent glioblastoma on bevacizumab: A subset analysis of the CABARET trial.
    Olafson LR; Siddell AH; Field KM; Byrnes M; Rapkins RW; Ng B; Nixdorf S; Barnes EH; Johns TG; Yip S; Simes J; Nowak AK; Rosenthal MA; McDonald KL
    J Clin Neurosci; 2019 Dec; 70():157-163. PubMed ID: 31582283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic options in recurrent glioblastoma--An update.
    Seystahl K; Wick W; Weller M
    Crit Rev Oncol Hematol; 2016 Mar; 99():389-408. PubMed ID: 26830009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience.
    D'Alessandris QG; Montano N; Cenci T; Martini M; Lauretti L; Bianchi F; Larocca LM; Maira G; Fernandez E; Pallini R
    Acta Neurochir (Wien); 2013 Jan; 155(1):33-40. PubMed ID: 23132371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of dovitinib (TKI258) in recurrent glioblastoma.
    Schäfer N; Gielen GH; Kebir S; Wieland A; Till A; Mack F; Schaub C; Tzaridis T; Reinartz R; Niessen M; Fimmers R; Simon M; Coch C; Fuhrmann C; Herrlinger U; Scheffler B; Glas M
    J Cancer Res Clin Oncol; 2016 Jul; 142(7):1581-9. PubMed ID: 27100354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.